1
Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
| Product Code | LU-65M; LU-65; LU65; Lu65; C-Lu-65; C-Lu65 |
| Species | Human |
| Cat.No | ABC-TC0613 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Lung |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Lung Cancer Cell Lines |
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
Amodio, V., Yaeger, R., Arcella, P., Cancelliere, C., Lamba, S., & Lorenzato, A. et al. (2020). EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer. Cancer Discovery, CD-20-0187. https://doi.org/10.1158/2159-8290.cd-20-0187
LU65 cells serve as an NSCLC research model with lines like A549 and PC9 to study molecular mechanisms of cancer development and progression, including the role of KRAS and TP53 genes. They investigate drug resistance, particularly KRAS-mutant resistance to therapies like sotorasib, while exploring pathway interplay affecting drug response. These cells identify therapeutic targets through CRISPR-Cas9/drug screens, demonstrating that WEE1 inhibition enhances KRAS-targeted therapy efficacy. Additionally, LU65 enables studies on cell growth/proliferation/survival factors, immunohistochemistry for cellular characterization, and research on colony-stimulating factors in leukocytosis and prostaglandin production.
